BACKGROUND: Asthma is a common chronic inflammatory disease of the airways characterized by @entity1224 and hyperresponsiveness. @entity4443 ( @entity15490 ) are lipid mediators that contribute to many aspects of @entity565 pathogenesis. As the LT pathway is relatively @entity134 -resistant, its blockade by alternative strategies is a desirable component of @entity565 management. @entity6954 LT (cysLT) receptor 1 antagonists (LTRAs) have been utilized worldwide for more than 10years, and while their efficacy in @entity565 is well accepted, their limitations are also evident. SCOPE OF REVIEW: In this review, we summarize the biological effects of LTs in @entity565 , review recent advances in LT receptors, and consider possible new therapeutic targets in the LT pathway that offer the potential to achieve better control of @entity565 in the future. MAJOR CONCLUSIONS: CysLTs play pathogenetic roles in many aspects of @entity565 , and blockade of cysLT receptor 1 by currently available LTRAs is certainly beneficial in disease management. On the other hand, the limitations of LTRAs are also apparent. Recent studies have revealed new receptors for cysLTs other than classical cysLT receptors 1 and 2, as well as the potential importance of LTB(4) in @entity565 . GENERAL SIGNIFICANCE: Recent findings provide clues to new approaches for targeting the LT pathway that may overcome the current limitations of LTRAs and achieve superior control of @entity565 . This article is part of a Special Issue entitled: Biochemistry of Asthma.

XXXX and airway inflammation.

@entity4443 :: ('MESH:D015289', 'Chemical') :: ['Leukotrienes'] @entity565 :: ('MESH:D001249', 'Disease') :: ['asthma'] @entity15490 :: ('CHEBI:73575', 'Chemical') :: ['LTs'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid'] @entity6954 :: ('CHEBI:23511', 'Chemical') :: ['Cysteinyl'] @entity1224 :: ('MESH:D000402', 'Disease') :: ['airway obstruction']
@entity4443 :: (MESH:D015289,Chemical) :: ['Leukotrienes']
